Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

7 Jun 2022

Leuven, BELGIUM, Boston, MA, USJUNE 7, 2022   Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022.

The KININ2022 presentation is available under Conferences and Events within the Investors section of the Company’s  website.

Overview:  THR-149, a bicyclic peptide identified by a combination of phage-based selections and directed medicinal chemistry, is a potent and specific inhibitor of plasma kallikrein. In preclinical studies, THR-149 effectively blocked the release of bradykinin in the vitreous and reduced the level of edema and retinal vascular leakage in rodent models. 

Results: IVT-PK and IV-PK data were analyzed based on a mono-compartmental pharmacokinetic model, leading to ocular and systemic half-lives of 36 h and 1.1 h, respectively. The model indicates IVT administration of THR-149 reduces the four DME disease hallmarks: retinal vascular leakage, retinal edema, retinal inflammation and reactive gliosis.

THR-149 is being developed as a potential new standard of care for the up to 50% of diabetic macular edema (DME) patients showing suboptimal response to anti-VEGF therapy.  Oxurion is currently evaluating THR-149 for the treatment of DME in Part B, the second part of its two-part Phase 2 KALAHARI trial. 

Press release attachment: 
Tags: 
Event; THR-149